Retinoblastoma—Current Therapeutic Challenges and Promising New Approaches

Dear Colleagues,

Retinoblastoma (RB) is the most common primary intraocular tumor with an incidence of 1 in 14000 to 1 in 20000 per childbirths. Untreated, the tumor expands, may extend beyond the eye and develop metastatic spread. The advent of novel routes of chemotherapy administration, including intra-arterial, intravitreal and intracameral injections, has considerably improved the overall eye survival rate, eradicating the need for external beam radiotherapy, eliminating the risk of radio-induced malignancies, and reducing the indications for systemic chemotherapy. These new therapeutic frontiers in the conservative management of RB can be further extended provided that new biological markers are validated to detect minimally disseminated disease, promoting tolerance zero for metastasis, and that new strategies and drugs are developed to overcome drug resistance, multi drug resistances and toxicities, as well as to improve the visual outcome and quality of life. Here, we aim at providing an overview on retinoblastoma by highlighting the progress made in treatment regimens. In this context, we welcome reviews and research articles summarizing the current state of the art in RB screening and treatment and future challenges as well as basic, preclinical and clinical studies. We are looking for studies on genes and miRNAs involved in the etiology and progression of RB, the potential impact of liquid biopsy and the development of chemoresistances. Other possible topics are promising new approaches including charged particle treatment, toxic chorioretinopathies, tumor invasion, metastasis and recurrence.

Prof. Dr. Nicole Dünker
Prof. Dr. Norbert Bornfeld
Prof. Dr. Francis L. Munier
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.